MK1084-012: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Lo

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06997497?term=kandlelit-012&viewType=Card&limit=10&sort=@relevance&rank=1

Contact name

Laura Morse Cucci

Clinical trials study type

Oncology - Gastrointestinal

Clinical trials trial status

Open to Accrual

IRB number

2362784

Principal investigator

Gang Chen, MD, PhD

Clinical trials study number

G2503

Phone

443-849-3122

Fax

443-849-3777

Clinical trials title (full)

MK1084-012: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)